证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-026 | --- | --- | --- | |----------------|-------------------------------|------------------------------------------------------------| | | | | | 投资者关系活动 | R | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | BNP | 资管、奥博资本、高盛资管、红衫资本、泓德基金、民 | | | | 生证券、平安养老、平安资管、浦银安盛、天弘基金、文渊 | | | | 资本、浙商医药、中信建投、中信证券、中邮证券共 15 家机 | | | 构。 | | | 时间 | 2024 年 11 月 14 日 | -2024 年 11 月 15 日 | | 参会方式 | 电话会议 ...

Investment Rating - The report maintains a "Recommended" rating for Haier Biomedical (688139) [1] Core Views - The low-temperature storage business shows significant recovery, while non-storage new businesses continue to perform well [1] - Despite external pressures, both domestic and international businesses achieved steady growth, with Q3 2024 revenue increasing by 0.51% year-on-year and 4.17% quarter-on-quarter [1] - The company has successfully accelerated order delivery in overseas projects, leading to a 13.36% year-on-year increase in overseas revenue in Q3 2024 [1] - Non-storage new business revenue grew by 21% year-on-year in the first three quarters of 2024, becoming a key driver for sustainable growth [1] - The net profit margin for Q3 2024 was 14.29%, showing a decline due to non-recurring losses, but is expected to recover as these impacts diminish [1] - The gross profit margin for Q3 2024 was 49.04%, indicating a steady increase [1] Financial Summary - Total revenue for Q1-3 2024 was 1.782 billion yuan, a decrease of 2.43% year-on-year, with a net profit of 309 million yuan, down 13.45% [1] - Q3 2024 revenue was 559 million yuan, with a net profit of 75 million yuan, reflecting a 5% decline year-on-year [1] - The company adjusted its net profit forecasts for 2024-2026 to 410 million, 510 million, and 620 million yuan, with corresponding year-on-year growth rates of 1.4%, 23.5%, and 21.7% [1][2] - The estimated price-to-earnings ratios for 2024-2026 are 26, 21, and 18 times, respectively [2]

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-025 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | R | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 安信基金、百年资管、东吴证券、民生加银基金、浦银安盛 | | | | 基金、拾贝投资、信达证券、兴业证券、中信建投证券共 9 | | | 家机构。 | | | 时间 | 2024 年 11 月 7 | 日-2024 年 11 月 8 日 | | 参会方式 | 电话会议 | | | 上市公司接待人 | | 董事会秘书黄艳莉、证券事务代表刘向青 | | 员姓名 | | ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown initial signs of improvement in overseas projects, with expectations for synergies from acquisitions and new growth drivers in emerging industries [2][4] - The revenue for the first three quarters of 2024 was 1.782 billion yuan, a decrease of 2.4% year-on-year, while the net profit attributable to the parent company was 309 million yuan, down 13.5% [2] - The company is expected to see a recovery in Q4 2024, driven by improved order delivery in storage and overseas projects [4] Summary by Sections Financial Performance - Total revenue for 2022 was 2.864 billion yuan, with a year-on-year growth of 34.72%. In 2023, revenue decreased to 2.281 billion yuan, a decline of 20.36%. Projections for 2024, 2025, and 2026 are 2.418 billion yuan, 2.780 billion yuan, and 3.225 billion yuan respectively, with expected growth rates of 6.00%, 15.00%, and 16.00% [1][4] - The net profit attributable to the parent company was 600.79 million yuan in 2022, dropping to 406.07 million yuan in 2023, with forecasts of 416.49 million yuan, 502.12 million yuan, and 593.87 million yuan for 2024, 2025, and 2026 respectively [1][4] - The latest diluted EPS for 2022 was 1.89 yuan per share, decreasing to 1.28 yuan in 2023, with projections of 1.31 yuan, 1.58 yuan, and 1.87 yuan for the following years [1] Business Segments - In Q1-Q3 2024, the life sciences segment generated 863 million yuan in revenue, an increase of 3.4%, while the medical innovation segment saw a decline of 7.4% with 913 million yuan in revenue [3] - Domestic revenue for the same period was 1.248 billion yuan, up 3.0%, while overseas revenue was 527 million yuan, down 13.3% [3] - The storage business faced challenges due to delays in solar vaccine project orders, but showed significant recovery in Q3, with overseas project order delivery accelerating [3][4] Growth Drivers - Non-storage new industries contributed significantly, accounting for 45% of revenue in Q1-Q3 2024, with an expected growth rate of over 20% for the year [3] - The integration of acquisition targets has been positive, with the liquid nitrogen tank business achieving a CAGR of 30% since its addition, and public health information technology business revenue growing over 40% [3][4]

证券代码：688139 证券简称：海尔生物 公告编号：2024-071 青岛海尔生物医疗股份有限公司 关于职工代表监事辞职暨补选职工代表监事的公告 青岛海尔生物医疗股份有限公司（以下简称"公司"）监事会于近日收到公司 第三届监事会职工代表监事郝倩倩女士递交的书面辞职报告。郝倩倩女士因个人原 因，申请辞去公司第三届监事会职工代表监事职务，辞任后不再担任公司任何职务。 截至本公告披露日，郝倩倩女士未持有公司股份，不存在应当履行而未履行的承诺 事项。 二、关于补选职工代表监事的情况 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、职工代表监事辞职情况 郝倩倩女士在任期间恪尽职守、勤勉尽职，为公司规范运作发挥了积极作用。 公司及监事会谨向郝倩倩女士在任期间为公司所做的贡献表示衷心感谢！ 为保证公司监事会的正常运作，根据《中华人民共和国公司法》等相关法律、 法规以及规范性文件和《公司章程》的相关规定，公司于 2024 年 11 月 6 日召开职 工代表大会，经与会职工代表一致同意，选举杨增辉先生（简历详见附件）为公司 第三届监 ...

Investment Rating - The investment rating for Haier Biomedical is maintained at "Buy" [1] Core Views - The company faced pressure in its performance during the first three quarters of 2024, but signs of a turning point in operations are emerging [2] - Revenue for Q1-Q3 2024 was 1.782 billion yuan, a year-over-year decrease of 2.43%, while net profit attributable to shareholders was 309 million yuan, down 13.45% year-over-year [2] - The company is adjusting its profit forecasts for 2024-2026, expecting net profits of 434 million, 533 million, and 655 million yuan respectively [2] Financial Performance Summary - For Q1-Q3 2024, the gross margin was 48.51%, down 2.35 percentage points, and the net margin was 17.9%, down 2.12 percentage points [2] - Sales expense ratio decreased to 11.88%, while management expense ratio slightly increased to 7.51% [2] - The company’s revenue from non-storage business reached 45% of total revenue, growing by 21% year-over-year [3] Market Performance - Domestic revenue reached 1.248 billion yuan, an increase of 2.97% year-over-year, while overseas revenue was 527 million yuan, a decrease of 13.32% year-over-year [3] - In Q3 2024, the company achieved revenue of 559 million yuan, a year-over-year increase of 0.51% [2][3] Segment Performance - The life sciences segment generated 863 million yuan in revenue for Q1-Q3 2024, a year-over-year increase of 3.36% [4] - The innovative medical segment reported revenue of 913 million yuan, down 7.42% year-over-year [4] Valuation Metrics - The expected earnings per share (EPS) for 2024-2026 are projected at 1.36, 1.68, and 2.06 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 24.0, 19.5, and 15.9 [2][5]

证券代码：688139 证券简称：海尔生物 公告编号：2024-070 2023 年年度权益分派实施完毕后，公司根据相关规定对回购股份价格上限进 行相应调整，自 2024 年 6 月 6 日起，回购价格上限调整为不超过 49.4887 元/股 （含），具体内容详见公司于 2024 年 6 月 7 日在上海证券交易所网站 （www.sse.com.cm）上披露的《青岛海尔生物医疗股份有限公司关于 2023 年年度 权益分派实施后调整回购股份价格上限的公告》（公告编号：2024-039）。 青岛海尔生物医疗股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/9 | | | --- | --- | --- | | 回购方案实施期限 | 待第二届董事会第十七次会议审议通过后 | 12 个月 | | 预计回购金额 | 2,500 万元~5,000 万元 | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 ...

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-024 | --- | --- | --- | |----------------|--------------------------|---------------------------------------------------------------| | | | | | | | | | 投资者关系活动 | R | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | Sage Partners Limited、Superstring Capital Management LP 、东 | | | | 吴证券、国联安基金、诺德基金、融通基金、睿远基金、西 | | | | 南证券、兴业证券、中信保诚基金、中信建投证券共 11 家机 | | | 构。 | | | 时间 | 2024 年 10 月 31 | ...

证券代码：688139 证券简称：海尔生物 青岛海尔生物医疗股份有限公司 投资者关系活动记录表 编号：2024-023 | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | R | 特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 □电话会议 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 共 62 | 家机构，参会机构名单详见附表。 | | 时间 | 2024 年 10 月 29 | 日-2024 年 10 月 30 日 | | 参会方式 | 电话会议 | | | 上市公司接待人 | | 公司董事、总经理刘占杰先生及公司管理层 | | 员姓名 | | | | 投资者关系活动 | | 第一部分 总经理介绍公司近况 | | 主要内容介绍 | | 在外部环境压力 ...

证券代码：688139 证券简称：海尔生物 公告编号：2024-068 青岛海尔生物医疗股份有限公司 关于新增 2024 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 本事项无需提交股东大会审议。 日常关联交易对上市公司的影响：青岛海尔生物医疗股份有限公司（以 下简称"海尔生物"或"公司"）与关联方发生的日常关联交易，是公司日常经 营活动的需要，关联交易定价遵循公允、合理的原则，不存在损害公司及全体股 东特别是中小股东利益的行为，不会对关联方形成依赖，不会影响公司独立性。 一、 日常关联交易的基本情况 （一）日常关联交易履行的审议程序 公司于 2024 年 7 月 19 日召开了第三届董事会第一次会议、第三届监事会第 一次会议、第三届董事会独立董事专门会议第一次会议、第三届董事会审计委员 会第一次会议，分别审议通过了《关于新增关联方及新增 2024 年度日常关联交 易预计的议案》，关联董事、监事均已回避表决，出席会议的非关联董事、监事 一致同意通过该议案。此次新增的关联方为上 ...